Doximity (DOCS) Laps the Stock Market: Here's Why
Doximity (DOCS) concluded the recent trading session at $20.99, signifying a +2.79% move from its prior day's close.
Zacks Investment Research7/27/2026Neutral
DOCS
Doximity IncNYSEHEALTHCAREHEALTH INFORMATION SERVICES
Key Statistics
Market Cap
$3.77B
P/E Ratio
21.42
EPS
$0.98
Beta
1.29
52W High
$76.51
52W Low
$17.15
50-Day MA
$20.86
200-Day MA
$34.72
Dividend Yield
—
Profit Margin
30.40%
Forward P/E
14.29
PEG Ratio
0.59
About Doximity Inc
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Fundamentals
| Revenue (TTM) | $644.86M |
| Gross Profit (TTM) | $574.54M |
| EBITDA | $228.79M |
| Operating Margin | 21.60% |
| Return on Equity | 19.30% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $3.45 |
| Book Value | $5.19 |
| Price-to-Book | 3.92 |
| Price-to-Sales (TTM) | 5.85 |
| EV/Revenue | 4.629 |
| EV/EBITDA | 13.02 |
| Quarterly Earnings Growth (YoY) | -69.00% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $128.86M |
| Float | $127.40M |
| % Insiders | 2.78% |
| % Institutions | 100.14% |
Historical Volatility
HV 10-Day
35.28%
HV 20-Day
39.66%
HV 30-Day
41.14%
HV 60-Day
71.87%
HV Rank
31.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($24.61 target)
5
Strong Buy4
Buy12
Hold1
Strong SellLatest News
Reasons to Retain Doximity Stock in Your Portfolio for Now
DOCS is ramping up AI across physician workflows and enterprise tools, but weak pharma ads and higher AI spending may test near-term growth.
Zacks Investment Research7/17/2026Negative
Doximity to Release Fiscal 2027 First Quarter Results on August 6, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.
Business Wire7/16/2026Neutral
Did Doximity Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire7/3/2026Neutral
Doximity: Everyone Is Focused On The Guidance While Missing The Valuation And AI Stories
Doximity issued conservative FY2027 guidance, projecting 4% revenue growth and a 49% adjusted EBITDA margin, triggering a post-earnings stock selloff. I view the selloff as a temporary dislocation and a compelling buying opportunity for value investors given DOCS's resilient core platform usage. Management emphasized record physician engagement and continued dominance of DOCS's core products despite macroeconomic and regulatory headwinds.
Seeking Alpha6/30/2026Positive
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Doximity (DOCS) concluded the recent trading session at $19.85, signifying a -4.7% move from its prior day's close.
Zacks Investment Research6/25/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire6/25/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire6/18/2026Neutral
Doximity (DOCS) Advances While Market Declines: Some Information for Investors
Doximity (DOCS) closed at $20.89 in the latest trading session, marking a +1.02% move from the prior day.
Zacks Investment Research6/16/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire6/16/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DOCS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026